De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Aptahem Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mikael Lindstam

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

CEO

Mikael Lindstam (58 yo)

less than a year

Tenure

Mr. Mikael Lindstam served as Director at Cyxone AB (publ) since 2015 until May 30, 2023 and served its Chief Operating Officer. Mr. Lindstam is Co-Founder of Aptahem AB (publ) and serves as the Chief Exec...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bert Junno	Co-Founder & Chairman of the Board	4.8yrs	geen gegevens	geen gegevens
Mikael Lindstam	Co-Founder	less than a year	geen gegevens	0.067% SEK 15.2k
Theresa Comiskey Olsen	Director	no data	geen gegevens	0.041% SEK 9.3k
Johan Lindh	Director	no data	geen gegevens	0.095% SEK 21.6k
Anders Bylock	Chairman of the Scientific Advisory Board	8.8yrs	geen gegevens	geen gegevens
Mats Eriksson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van APTA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Aptahem Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Aptahem AB (publ), Annual General Meeting, May 15, 2024

Aptahem AB (publ), Annual General Meeting, Jun 01, 2023

No independent directors

Aptahem (Publ) Announces Executive Changes

No independent directors

Aptahem Appoints Karin Aschan as New Regulatory Affairs Director

Recent updates

Aptahem AB (Publ) Announces Completion of Double-Blind Randomised Placebo-Controlled Phase 1 Study

Second quarter 2024 earnings released

Aptahem AB (publ) to Report Q2, 2024 Results on Aug 30, 2024

Aptahem AB (publ) Reports the FIH Study on Apta-1 Has Been Finalized

First quarter 2024 earnings released

Aptahem AB (publ) to Report Q3, 2024 Results on Jun 19, 2024

Aptahem Plans to Perform A Proof-Of-Concept Phase 2 Study in Patients with Its Lead Candidate Apta-1

Aptahem Reports Top Line Results from the Fih Study with Apta-1

New major risk - Shareholder dilution

Aptahem AB (publ), Annual General Meeting, May 15, 2024

Full year 2023 earnings released: kr0.058 loss per share (vs kr0.053 loss in FY 2022)

Aptahem AB (publ) Reports Promising Outcome from the Additional Analyses on the Mechanism on Lead Candidate Apta-1 in the FIH Study

Second quarter 2023 earnings released

Aptahem AB (publ) Announces in Aptahem's FIH Study Further Analytic Studies Will Be Performed

Aptahem AB (publ) to Report Nine Months, 2023 Results on Oct 26, 2023

Aptahem AB (Publ) Announces the Completion of an Additional Cohort in the Ongoing Double-Blinded Randomized Placebo Controlled Clinical First in Human Study

Dutch Ethics Committee Approves Aptahem AB (Publ)'s Second Dose Cohort in the Clinical First in Human Study in Healthy Volunteers

Aptahem AB (publ), Annual General Meeting, Jun 01, 2023

Aptahem AB (publ) Announces First Cohort Dosed in Aptahem's FIH Study

Aptahem AB (Publ), Announces First Subjects Dosed in Fih Study

Aptahem AB (publ) Announces First Subjects Screened in Aptahem's FIH Study with Apta-1

Aptahem Reports Added Positive and Significant Biological Effect in an Extended Corona Virus-Induced Acute Lung Injury Model Treated with Apta-1

No independent directors

Aptahem AB (publ) Receives Full Regulatory Approval to Start the FIH Study with Apta-1

Aptahem AB (publ) Submit Regulatory Approval to Initiate Clinical Phase 1 Study

Aptahem AB (publ) Confirms Lead Candidate Apta-1 Shows Very Good Tolerability in GLP Tox Studies

Aptahem (Publ) Announces Executive Changes

No independent directors

Aptahem AB (publ) Reports Additional Positive Biological Effect in A Corona Virus-Induced Acute Lung Injury Model Treated with Apta-1

Aptahem Appoints Karin Aschan as New Regulatory Affairs Director

Aptahem AB (Publ) Appoints Thomas Rupp as CMC Director

Aptahem AB (publ) Receives Intention to Grant from the European Patent Office for the Protection of Patent Family 2

Aptahem AB (Publ) Receives Notice of Allowance from the US Patent Office

Aptahem Signs A Non Binding Term Sheet for Development, Manufacturing and Distribution of Apta-1 for Sepsis in Europe

Aptahem AB (publ) Signs Agreement with Collaboration Partner LGC Group to Initiate the GMP Manufacturing of Apta-1

New 90-day low: kr1.30

New 90-day low: kr1.33

Aptahem AB (publ) to Report Fiscal Year 2020 Final Results on Apr 08, 2021

New 90-day low: kr1.38

New 90-day low: kr1.39

New 90-day low: kr1.61

New 90-day low: kr1.76

Aptahem AB (publ) to Report Q3, 2020 Results on Nov 30, 2020

New 90-day low: kr2.07

New 90-day low - kr2.07

First half earnings released

New 90-day high - kr3.18

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd